Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Elevation Oncology, Inc. (ELEV : NSDQ)
 
 • Company Description   
Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK.

Number of Employees: 35

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.64 Daily Weekly Monthly
20 Day Moving Average: 45,120 shares
Shares Outstanding: 23.25 (millions)
Market Capitalization: $84.64 (millions)
Beta:
52 Week High: $16.22
52 Week Low: $2.28
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 54.89% 69.72%
12 Week 2.25% 10.94%
Year To Date -39.53% -28.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
888 Seventh Ave.12th Floor
-
New York,NY 10106
USA
ph: 716-371-1125
fax: -
ir@elevationoncology.com https://elevationoncology.com
 
 • General Corporate Information   
Officers
Shawn Leland - President; Chief Executive Officer and Director
Steven A. Elms - Chairman
Joseph J. Ferra - Chief Financial Officer and Corporate Secretary
R. Michael Carruthers - Director
Timothy Clackson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 28623U101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 23.25
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $84.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.80 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.84 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.68
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -80.49%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -31.06
12/31/21 - -28.76
09/30/21 - -
ROA
03/31/22 - -29.41
12/31/21 - -27.44
09/30/21 - -
Current Ratio
03/31/22 - 12.86
12/31/21 - 17.00
09/30/21 - 17.84
Quick Ratio
03/31/22 - 12.87
12/31/21 - 17.00
09/30/21 - 17.84
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.33
12/31/21 - 6.06
09/30/21 - 6.44
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©